Evaluation of the Feasibility and Safety of ENCER for Cancer Treatment-Related Fatigue in Patients Receiving Chemotherapy or Radiotherapy
Recruiting now · Early Phase 1 · Has a placebo group
Conditions studied: Fatigue Related to Cancer Treatment
In brief
This is a feasibility, double blind, placebo-controlled clinical study designed to evaluate the effect of 'Encer' on Cancer treatment Related Fatigue. 'Encer' is a combination of 5 Homeopathic Medical Product (HMP). The five HMPs are registered in the Homeopathic Pharmacopeia of the United States and the current investigational treatment 'Encer' is authorized for over-the-counter sales in the USA by NDC number. The study aims to test the efficacy of 'Encer' in treating Cancer Treatment-Related Fatigue (CTRF) among cancer patients treated with chemotherapy and or radiotherapy using the Physiological measurements using Garmin vivosmart 5 and the Functional Assessment of Chronic Illness Therapy -Fatigue (FACIT-F). This feasibility study will include patients that will be randomly assigned to either Placebo or Treatment in 1:1 ratio.
Key facts
- Study ID
- NCT07707648
- Run by
- Beaura for Para Pharmaceutical Products Trading LLC
- People needed
- 74
- Starts
- 2025-10-01
- Expected to finish
- 2026-10-01
- Last updated by the study team
- 2026-07-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subject's informed consent
- Either male or female
- Age 18 and above
- Diagnosed with cancer (any type of solid tumor)
- Patients planned for their initial treatment or a new regimen of chemotherapy, (at least 4 treatments planned within 12 weeks) a new regimen of radiotherapy (at least 15 fractions planned)
- Able to interface with digital questionnaire sent to the patient electronically
- Willing to wear a smartwatch that will detect physiological measurements for the duration of the trial
- Not currently treated with homeopathic remedy (for at least one week prior to study treatment)
You may not qualify if…
- Unable to give informed consent
- Planned Radiotherapy for less than 15 fractions
- Chemotherapy anticipated for less than 12 weeks, or fewer than 4 treatments
- Life expectancy of less than 3 months
- Patient is a dependent of the sponsor, of the investigational team or his/her immediate family
- Pregnant or nursing women
Where it is running
- Assuta Medical Centers Ramat HaHayal — Tel Aviv, Israel (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.